Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aimed at kidney disease shows promise in early trial

NCT ID NCT07096843

Recruiting now Disease control Sponsor: Climb Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 2 trial is testing a new drug, budoprutug (also known as TNT119), in 45 people with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The study aims to see if the drug is safe and can help patients achieve remission. Participants receive the drug as an IV infusion on four separate days over about six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
budoprutug (TNT119)
What this could lead to
If successful, this could point toward a new treatment option for primary membranous nephropathy, potentially helping patients achieve remission and avoid long-term kidney damage.
What could go wrong
This is an early-phase, open-label trial with only 45 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MEMBRANOUS NEPHROPATHY

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Climb Bio Investigative Site #101

    RECRUITING

    Clifton Park, New York, 12065, United States

  • Climb Bio Investigative Site #104

    RECRUITING

    Sherman, Texas, 75092, United States

  • Climb Bio Investigative Site #105

    RECRUITING

    Orlando, Florida, 32086, United States

  • Climb Bio Investigative Site #106

    RECRUITING

    Indianapolis, Indiana, 46268, United States

  • Climb Bio Investigative Site #108

    RECRUITING

    Atlanta, Georgia, 30342, United States

  • Climb Bio Investigative Site #110

    RECRUITING

    Denver, Colorado, 80220, United States

  • Climb Bio Investigative Site #111

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • Climb Bio Investigative Site #204

    RECRUITING

    Taichung, 404, Taiwan

  • Climb Bio Investigative Site #205

    RECRUITING

    Taipei, 112, Taiwan

  • Climb Bio Investigative Site #401

    RECRUITING

    Beijing, Cheng District, 100034, China

  • Climb Bio Investigative Site #402

    RECRUITING

    Wuxi, Jiangsu, 214023, China

  • Climb Bio Investigative Site #403

    NOT_YET_RECRUITING

    Beijing, Changping District, 102218, China

  • Climb Bio Investigative Site #404

    NOT_YET_RECRUITING

    Yibin, Sichuan, 644000, China

  • Climb Bio Investigative Site #405

    NOT_YET_RECRUITING

    Jinan, Shandong, 250014, China

  • Climb Bio Investigative Site #406

    NOT_YET_RECRUITING

    Beijing, Xicheng District, 100044, China

  • Climb Bio Investigative Site #407

    NOT_YET_RECRUITING

    Xi'an, Shaanxi, 710061, China

  • Climb Bio Investigative Site #408

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, 518036, China

  • Climb Bio Investigative Site #409

    NOT_YET_RECRUITING

    Yantai, Shandong, 264000, China

  • Climb Bio Investigative Site #501

    RECRUITING

    Porto Alegre, 90020-090, Brazil

  • Climb Bio Investigative Site #502

    RECRUITING

    Belo Horizonte, 30150-320, Brazil

  • Climb Bio Investigative Site #503

    RECRUITING

    São Paulo, 05403-000, Brazil

  • Climb Bio Investigative Site #504

    RECRUITING

    São Paulo, 05403-000, Brazil

  • Climb Bio Investigative Site #505

    RECRUITING

    Minas Gerais, 36010-570, Brazil

  • Climb Bio Investigative Site #506

    RECRUITING

    Pernambuco, 50670-901, Brazil

  • Climb Bio Investigative Site #601

    RECRUITING

    CABA, C1111, Argentina

  • Climb Bio Investigative Site #604

    RECRUITING

    CABA, C1425, Argentina

  • Climb Bio Investigative Site #606

    RECRUITING

    Santa Fe, S3000, Argentina

  • Climb Bio Investigative Site #701

    NOT_YET_RECRUITING

    Temuco, Araucania, 4811230, Chile

  • Climb Bio Investigative Site #702

    NOT_YET_RECRUITING

    Santiago, Santiago Metropolitan, 8320165, Chile

  • Climb Bio Investigative Site #703

    NOT_YET_RECRUITING

    Valdivia, Los Ríos Region, 5020000, Chile

  • Climb Bio Investigative Site #802

    RECRUITING

    Ternopil, 46002, Ukraine

  • Climb Bio Investigative Site #803

    RECRUITING

    Ivano-Frankivsk, 76008, Ukraine

  • Climb Bio Investigative Site #804

    RECRUITING

    Rivne, 33027, Ukraine

  • Climb Bio Investigative Site #805

    RECRUITING

    Kyiv, 03151, Ukraine

  • Climb Bio Investigative Site #901

    RECRUITING

    Tbilisi, 0144, Georgia

  • Climb Bio Investigative Site #902

    RECRUITING

    Tbilisi, 0114, Georgia

  • Climb Bio Investigative Site #903

    RECRUITING

    Tbilisi, 0112, Georgia

  • Climb Bio Investigative Site# 201

    RECRUITING

    Taipei, 110, Taiwan

  • Climb Bio Investigative Site# 202

    RECRUITING

    Taipei, 100, Taiwan

  • Climb Bio Investigative Site# 203

    RECRUITING

    Taipei, 235, Taiwan

  • Climb Bio Investigative Site# 602

    RECRUITING

    Buenos Aires, B1629, Argentina

  • Climb Bio Investigative Site# 603

    RECRUITING

    Buenos Aires, B1888, Argentina

  • Climb Bio Investigative Site# 801

    RECRUITING

    Kyiv, 02125, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.